ISRIB A15 vs Modafinil: A Chemist's Honest Comparison

You've been on modafinil for a while. Maybe it's working. Maybe it stopped working, or works but leaves you with that slightly-overclocked feeling — alert but also weirdly flat, like the lights are on but something else is missing.

That's usually when people start asking about ISRIB A15.

I'm not going to tell you A15 is better than modafinil. That's not a useful frame. They do fundamentally different things, and which one matters to you depends entirely on what's actually wrong — or not wrong — with your cognition right now.

What modafinil actually does

Modafinil is a wakefulness-promoting agent. Its primary mechanism involves inhibiting dopamine reuptake and activating orexin neurons in the hypothalamus — the cells responsible for keeping you awake and alert. It works fast, the effects are obvious within an hour, and twenty years of human data have established that it's reasonably safe for most people.

What modafinil does not do: it doesn't improve how your neurons form memories. It doesn't touch protein synthesis. It doesn't address why your baseline cognition might have degraded over months of stress or overwork. It keeps you awake and focused. That's it. That's genuinely useful for a lot of people.

The downsides are well-documented. Anxiety in some users. Sleep disruption if taken too late. A kind of tunnel-vision focus that's great for grinding through repetitive tasks but can make creative or associative thinking harder. And tolerance — not dramatic, but real. The 200mg that felt crisp at month one often feels like 100mg by month six.

What ISRIB A15 does instead

A15 operates at a completely different level of biology.

Under chronic stress — and "chronic stress" here means anything from overwork to sleep debt to a difficult year — a cellular pathway called the Integrated Stress Response tends to become chronically activated. The ISR's job is to pause protein synthesis during emergencies. Short-term, this is adaptive. Long-term, it means your neurons are running with a reduced supply of the proteins required for memory consolidation and synaptic plasticity.

ISRIB targets eIF2B, a key regulatory complex in this pathway. By stabilizing eIF2B's active conformation, it allows protein synthesis to continue even when stress signals are present. You're not stimulating the brain — you're removing a brake.

The distinction matters practically. Modafinil gives you more wakefulness to work with. A15 potentially gives you back the cognitive capacity that chronic stress had been quietly suppressing.

The 2020 eLife paper is the one that made a lot of people in this space sit up. Old mice performing on spatial memory tasks like young mice — not "somewhat better." Like young mice. The result wasn't subtle, and it replicated across multiple cohorts in the Rosi/Walter labs at UCSF.

I'll be honest: when I first read that paper, I read it twice. Then I went back to the 2013 Sidrauski et al. data. Then the 2017 TBI work. The mechanistic story is unusually coherent for a compound this new.

The experience profile is different

This is where most comparisons fall short — they focus on mechanism and skip what the compounds actually feel like.

Modafinil: alertness is the primary experience. Focus follows from alertness. You're awake, you're online, the activation energy for starting tasks drops. The effect is obvious within 90 minutes and you know when it's wearing off.

A15: onset is slower. Most people report something starting to shift around day 2-3. It doesn't announce itself the way modafinil does. What users typically describe is less a feeling of being on something and more a feeling that a certain cognitive resistance is gone.

The memory effect is the other significant difference. Modafinil can improve working memory while it's active — you're alert, you retain more. But it doesn't meaningfully enhance long-term memory consolidation. A15, at least in the animal literature and in consistent user reports, seems to do exactly that.

Whether that tracks to human memory consolidation in the way the mouse data suggests — I don't know. I've watched enough reports to believe something real is happening. I can't tell you the exact mechanism is what we think it is.

Where modafinil still wins

If you need to be awake and functional in four hours — modafinil wins. No contest.

If you're doing shift work, cramming for an exam tomorrow, need to power through a 14-hour workday: modafinil is the tool for that. It has a fast onset, predictable dose-response, and twenty years of safety data in humans.

A15 doesn't replace that. It's not a stimulant, it doesn't give you energy in the direct sense, and the onset timeline means it's not something you reach for when you need to perform right now.

The use cases that make more sense for A15: you've noticed your baseline has degraded. The cognitive capacity you had two years ago — the ease of learning new things, the memory that just worked — isn't there anymore. You've been grinding through high-stress periods for long enough that something feels structurally different. Modafinil got you through those periods but didn't fix anything. That's the gap A15 is designed for.

The tolerance question

Modafinil tolerance is real and well-documented. Not dramatic, but after months of daily use most people end up cycling or increasing dose to maintain effect.

A15 tolerance data is limited — we're talking biohacker self-reports, not controlled trials. The consistent pattern in those reports is low tolerance buildup, which makes mechanistic sense: you're not flooding receptors with a ligand, you're stabilizing a protein complex. The ISR pathway doesn't have the same sensitization/desensitization dynamics as dopaminergic systems. That's the theoretical argument. I'd hold it loosely.

The honest comparison table

Who should actually consider A15

If your cognition is basically intact and you just need to work longer hours — modafinil is probably the right tool and you don't need A15.

If you've noticed your baseline has slipped — you're not processing as fast as you used to, memory feels sticky, learning new things takes more effort than it did — that's where the ISR hypothesis becomes relevant and A15 is worth researching seriously.

The people who report the clearest effects tend to share a common profile: sustained high-stress periods, often 12-24 months, during which they were functional but gradually less sharp. Not burnout in the clinical sense. Just erosion. A15 seems to address that erosion more directly than any stimulant does, because stimulants don't touch the underlying pathway.

A note on the data situation

Modafinil has human trials. ISRIB A15 does not — yet. Calico (Google's longevity arm) is running ISRIB trials in ALS patients as of 2024, which is meaningful, but that's original ISRIB and it's a disease population.

What we have for A15 in healthy humans is: a mechanistically coherent story, striking animal data, and a growing body of self-reports that are unusually consistent in their description of effects. That's more than most research chemicals, and less than a pharmaceutical. Anyone telling you otherwise in either direction is not being straight with you.

I use the phrase "research is promising, human data is limited" a lot. Here it's genuinely accurate, not just a legal disclaimer.

The comparison to modafinil ultimately comes down to what problem you're actually trying to solve. For acute wakefulness and focus: modafinil is still the more proven tool. For addressing the kind of slow cognitive degradation that accumulates under chronic stress — where the issue isn't alertness but something that feels more structural — A15 addresses a different, and arguably more upstream, target.

Whether that upstream target matters as much in humans as it does in the mouse models is the question the field hasn't answered yet. I think it does. I wouldn't be synthesizing it if I didn't. But I hold that with appropriate uncertainty.